Dimensional Fund Advisors LP increased its holdings in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 314.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 180,739 shares of the biopharmaceutical company’s stock after purchasing an additional 137,167 shares during the quarter. Dimensional Fund Advisors LP owned 0.49% of MacroGenics worth $3,165,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of the stock. Hood River Capital Management LLC increased its position in shares of MacroGenics by 2.3% during the 2nd quarter. Hood River Capital Management LLC now owns 576,193 shares of the biopharmaceutical company’s stock worth $10,089,000 after purchasing an additional 13,050 shares during the last quarter. Virtu KCG Holdings LLC acquired a new stake in shares of MacroGenics during the 2nd quarter worth about $232,000. Parametric Portfolio Associates LLC acquired a new stake in shares of MacroGenics during the 2nd quarter worth about $203,000. BB Biotech AG increased its position in shares of MacroGenics by 4.0% during the 2nd quarter. BB Biotech AG now owns 2,350,112 shares of the biopharmaceutical company’s stock worth $41,150,000 after purchasing an additional 90,112 shares during the last quarter. Finally, FMR LLC increased its position in shares of MacroGenics by 6.0% during the 2nd quarter. FMR LLC now owns 5,238,917 shares of the biopharmaceutical company’s stock worth $91,733,000 after purchasing an additional 295,553 shares during the last quarter. 85.81% of the stock is owned by hedge funds and other institutional investors.
A number of analysts recently issued reports on the company. ValuEngine raised MacroGenics from a “strong sell” rating to a “sell” rating in a research report on Friday, December 1st. Citigroup raised their price objective on MacroGenics from $18.00 to $22.00 and gave the stock a “neutral” rating in a research report on Friday, November 10th. Cowen reissued a “buy” rating on shares of MacroGenics in a research report on Wednesday, October 25th. Zacks Investment Research upgraded MacroGenics from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th. Finally, Stifel Nicolaus restated a “buy” rating and set a $34.00 target price on shares of MacroGenics in a report on Tuesday, September 12th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $30.10.
In other news, SVP Jon Marc Wigginton sold 5,000 shares of MacroGenics stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $20.00, for a total value of $100,000.00. Following the completion of the transaction, the senior vice president now owns 35,000 shares in the company, valued at approximately $700,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 8.30% of the company’s stock.
MacroGenics, Inc. (MGNX) opened at $19.57 on Wednesday. MacroGenics, Inc. has a twelve month low of $14.36 and a twelve month high of $28.48.
MacroGenics (NASDAQ:MGNX) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.19). The company had revenue of $1.70 million during the quarter, compared to analysts’ expectations of $5.50 million. MacroGenics had a negative net margin of 1,526.55% and a negative return on equity of 69.31%. The business’s quarterly revenue was down 48.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.97) EPS. analysts forecast that MacroGenics, Inc. will post -0.7 EPS for the current year.
WARNING: This article was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://ledgergazette.com/2017/12/06/macrogenics-inc-mgnx-stake-lifted-by-dimensional-fund-advisors-lp.html.
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.